Evaluation of treatment response to generic imatinib in newly diagnosed low-risk Ph+ CML patients
Anaesthesia, Pain & Intensive Care · 2026-10-04 · 30 (7)
DOI: 10.35975/apic.v30i7.3305 ↗Abstract
Background: Chronic myeloid leukemia (CML) is a myeloproliferative disorder driven by the BCR-ABL fusion gene. Imatinib, a first-generation tyrosine kinase inhibitor, remains the standard first-line therapy. Objective: To evaluate the treatment response to generic imatinib in newly diagnosed low-risk Philadelphia chromosome-positive CML patients. Methodology: This quasi-experimental study was conducted at the Department of Oncology, Allied Hospital Faisalabad, from February 2025 to March 2026. A total of 174 patients were enrolled using non-probability consecutive sampling. Eligible patients were newly diagnosed, untreated low-risk Ph+ CML cases aged 18–60 years. All patients received generic imatinib at a dose of 300 mg twice daily. Baseline and three-month assessments included complete blood counts and quantitative BCR-ABL PCR. Results: The mean age of patients was 38.6 ± 10.2 years, with 58.0% males. CHR was achieved in 85.6% of patients. Complete cytogenetic response was observed in 69.5%, while 29.9% achieved MMR at three months. There was a significant reduction in mean BCR-ABL levels from 78.4 ± 12.6% at baseline to 6.2 ± 3.8% at three months (p < 0.001). Significant associations with CHR were observed for age (p=0.041), gender (p=0.032), splenomegaly (p=0.018), and treatment compliance (p < 0.001). Most patients experienced no or mild adverse effects. Conclusion: Generic imatinib is an effective, safe, and well-tolerated treatment option in newly diagnosed low-risk Ph+ CML patients, demonstrating high early response rates and significant molecular reduction, with treatment adherence playing a critical role in achieving optimal outcomes. Keywords: Chronic myeloid leukemia, Imatinib, Generic drugs, BCR-ABL, Hematologic response, Molecular response Citation: Akbar MF, Tahir M, Munir R. Evaluation of Treatment Response to Generic Imatinib in Newly DiagnosedLow-Risk Ph+ CML Patients. Anaesth. pain intensive care 2026;30(7). DOI: 10.35975/apic.v30i7.3305 Received: March 31, 2026 ; Revised: xxxxxxxx; Accepted: May 04, 2026
EUVIMED